Keratoacanthoma - Keratoakantoma
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Tipiku Keratoakantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) huwa tumur tal-ġilda frekwenti magħruf għat-tkabbir rapidu tiegħu u l-potenzjal li jirrigressu waħdu. Tipikament iseħħ f'irġiel anzjani, ta 'ġilda ċara bi storja ta' ħsara mix-xemx. Filwaqt li t-tneħħija kirurġika bl-użu ta 'qtugħ jew kirurġija mikrografika Mohs hija t-trattament tas-soltu, hemm diversi għażliet ta' terapija oħra disponibbli.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) huwa tumur ta’ grad baxx li jibda f’ċerti glandoli fil-ġilda u jidher simili għal squamous cell carcinoma (SCC) taħt mikroskopju. Hemm dibattitu kontinwu dwar jekk il-KA għandhiex tiġi kklassifikata bħala forma ta' SCC invażiv.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) huwa t-tieni l-aktar tip ta’ kanċer komuni fin-nies, speċjalment fost individwi anzjani. Il-kirurġija hija tipikament użata biex tikkura cSCC, iżda għal xi pazjenti li ma jistgħux jagħmlu kirurġija jew jagħżlu li ma jagħmlux operazzjoni, jistgħu jiġu kkunsidrati għażliet oħra bħal trattamenti intrależjonali. Intużaw trattamenti intrależjonali tradizzjonali (methotrexate or 5-fluorouracil) , iżda għadha għaddejja riċerka dwar approċċi ġodda bħall-immunoterapija intrależjonali u l-viroterapija onkolitika. Hawnhekk, ser inħarsu lejn trattamenti intrależjonali differenti għal cSCC, li jvarjaw minn metodi klassiċi għal strateġiji avvanzati.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Taħt il-mikroskopju, keratoakantoma (keratoacanthoma) tixbah ħafna karċinoma taċ-ċelluli squamous. Filwaqt li xi patoloġisti jikklassifikaw keratoakantoma (keratoacanthoma) bħala entità distinta u mhux malinn, madwar 6% tal- keratoakantoma (keratoacanthoma) klinika u istoloġika tagħmel progress għal kanċer taċ-ċelluli squamous invażivi u aggressivi.
○ Djanjosi u Trattament
#Dermoscopy
#Skin biopsy